UTI Mutual Fund

UTI Healthcare Fund Direct-Growth

Equity: Sectoral-Pharma - Growth (Open ended)Download Report
SEBI Riskometer: Very HighCategory: Equity: Sectoral-PharmaBenchmark: BSE Healthcare Total Return IndexCheck Portfolio Overlap →
NAV: ₹401.84+0.78%
20 Nov 2026

Holdings Analysis

Equity, debt and cash allocation snapshot with market cap distribution for UTI Healthcare Fund Direct-Growth.

Asset Allocation

As on 31 Oct 2026
Equity
98.01%
Others
1.96%
Debt
0.03%

Market Cap Distribution

Large Cap (19.6%)
Mid Cap (37.0%)
Small Cap (43.4%)

Historical Asset Allocation

Asset31 Oct 202630 Sep 202631 Aug 202631 Jul 202630 Jun 202631 May 2026
Equity98.01%94.12%94.27%97.08%95.05%94.45%
Debt0.03%0.02%0.02%0.02%0.01%0.01%
Others (incl. cash)1.96%5.85%5.71%2.90%4.95%5.54%
Commodities0.00%0.00%0.00%0.00%0.00%0.00%
Real Estate0.00%0.00%0.00%0.00%0.00%0.00%

Portfolio Snapshot

No. of Securities
47
P/E Ratio
41.09
P/B Ratio
5.31
Top Holding %
7.44%
Top 5 Holdings %
28.18%
Top 10 Holdings %
46.57%
AUM
₹1,433 Cr
Expense Ratio
1.31%
Since Inception
16.58%
Max Drawdown
-0.27%
Alpha
0.92%
Sharpe Ratio
1.07

Top Portfolio Holdings by Weight

Latest portfolio holdings sorted by allocation weight. Includes instrument name, sector, number of shares, market value (₹ Cr) and percentage of net assets. Switch dates or categories using the controls below.
InstrumentSectorNo. of SharesValue (Rs. Cr)WeightChange
Sun Pharmaceutical Industries Ltd.Healthcare6,00,000106.667.44%-0.18%↓
Divis Laboratories Ltd.Healthcare94,70792.626.46%0.31%↑
Dr. Reddys Laboratories Ltd.Healthcare6,12,62982.835.78%0.55%↑
Ajanta Pharma Ltd.Healthcare1,75,00061.44.29%-0.53%↓
Max Healthcare Institute Ltd.Healthcare7,00,00060.24.20%1.41%↑
Gland Pharma Ltd.Healthcare1,79,92455.73.89%-0.17%↓
Apollo Hospitals Enterprise Ltd.Healthcare65,00054.913.83%0.81%↑
Alkem Laboratories Ltd.Healthcare1,02,51752.423.66%-0.04%↓
Lupin Ltd.Healthcare2,60,00052.293.65%0.75%↑
Global Health Ltd.Healthcare3,80,00048.273.37%0.41%↑
Cohance Lifesciences Ltd.Healthcare9,00,00039.992.79%-0.00%↓
Caplin Point Laboratories Ltd.Healthcare1,65,00038.372.68%-0.34%↓
Ipca Laboratories Ltd.Healthcare1,89,05636.452.54%-0.27%↓
Jupiter Life Line Hospitals Ltd.Healthcare12,50,00032.142.24%0.16%↑
Marksans Pharma Ltd.Healthcare10,00,00030.622.14%-0.12%↓
Glenmark Pharmaceuticals Ltd.Healthcare1,29,55829.782.08%-0.04%↓
Aurobindo Pharma Ltd.Healthcare1,76,85029.742.08%0.01%↑
Rainbow Childrens Medicare Ltd.Healthcare2,40,00029.252.04%-0.16%↓
Fortis Healthcare Ltd.Healthcare3,75,00028.812.01%-0.01%↓
Procter & Gamble Health Ltd.Healthcare50,00028.351.98%0.03%↑
1 / 3

Sector-wise Portfolio Allocation

Equity exposure by sector as a percentage of total net assets, tracked across recent portfolio dates. Identifies concentration risk and sector rotation trends in the fund's holdings.
Sector31 Oct 202630 Sep 202631 Aug 202631 Jul 202630 Jun 202631 May 2026
Healthcare
97.10%
93.12%
93.39%
96.35%
94.27%
93.67%
Services
0.91%
1.00%
0.88%
0.73%
0.78%
0.78%

Equity Insights

A detailed look at the equity holdings of this scheme — aggregated scores on value, momentum, quality parameters along with diversification and performance analysis.

Style Analysis

Value score

29.7 / 100

Weighted average Value score is 29.7. This indicates that portfolio is relatively reasonably valued using composite of value measures.

Price Momentum score

71.7 / 100

Weighted average Price Momentum score is 71.7. This indicates that portfolio has average momentum using composite of momentum measures.

Quality score

83.6 / 100

Weighted average Quality score is 83.6. This indicates that portfolio has high quality using composite of quality measures.

QVM score

71.2 / 100

Weighted average QVM score is 71.2. This indicates that portfolio has average QVM score and hence a neutral stance is warranted.

Red Flags

Earnings manipulation risk (Beneish M-score)
Following stocks have high risk of potential earnings manipulation (Beneish M-score > -1.78):
NameValue
Ajanta Pharma Ltd.-1.58
Viyash Scientific Ltd.-1.33
Alembic Pharmaceuticals Ltd.-1.51
Max Healthcare Institute Ltd.-1.68
Rainbow Childrens Medicare Ltd.-1.46
Jupiter Life Line Hospitals Ltd.-0.95
Indegene Ltd.-1.76
Anthem Biosciences Ltd.-1.63
Sudeep Pharma Ltd.0.66
Declining revenues
Following companies have seen their sales decline for 2 consecutive quarters (measured on yoy basis): Dr. Reddys Laboratories Ltd., Natco Pharma Ltd., Cohance Lifesciences Ltd., Syngene International Ltd.
High leverage
Following companies have debt to equity of greater than 2:
NameValue
Glenmark Pharmaceuticals Ltd.30.7

Frequently Asked Questions

What are the top holdings of UTI Healthcare Fund Direct-Growth?
The top holdings of UTI Healthcare Fund Direct-Growth as of 31 Oct 2026 are Sun Pharmaceutical Industries Ltd. (7.44%), Divis Laboratories Ltd. (6.46%), Dr. Reddys Laboratories Ltd. (5.78%), Ajanta Pharma Ltd. (4.29%), Max Healthcare Institute Ltd. (4.20%). These top 5 stocks together account for 28.18% of the total portfolio. You can view the complete holdings breakdown above.
How many stocks does UTI Healthcare Fund Direct-Growth hold in its portfolio?
UTI Healthcare Fund Direct-Growth holds 47 stocks in its portfolio as of 31 Oct 2026. The fund's portfolio size reflects the fund manager's investment approach, a more concentrated portfolio indicates higher conviction bets, while a larger number of holdings suggests a more diversified strategy.
What is the sector allocation of UTI Healthcare Fund Direct-Growth?
As of 31 Oct 2026, UTI Healthcare Fund Direct-Growth's top sector allocations are Healthcare (97.10%), Services (0.91%). You can find detailed sector allocation above.
What is the equity and debt allocation of UTI Healthcare Fund Direct-Growth?
As of 31 Oct 2026, UTI Healthcare Fund Direct-Growth has 98.01% allocated to equity, and 0.03% to debt. You can also check the historical trends above.
What is the market cap allocation of UTI Healthcare Fund Direct-Growth?
As of 31 Oct 2026, UTI Healthcare Fund Direct-Growth's market cap allocation is 19.57% in large caps, 36.99% in mid caps, and 43.43% in small caps.
What is the PE ratio of UTI Healthcare Fund Direct-Growth's portfolio?
The portfolio PE ratio of UTI Healthcare Fund Direct-Growth is 41.09 as of 31 Oct 2026. The portfolio PE ratio tells you how expensive or cheap the fund's holdings are relative to their earnings.
What is the credit quality of UTI Healthcare Fund Direct-Growth?
A credit rating breakdown is not available for UTI Healthcare Fund Direct-Growth — its non-equity allocation was 0.03% as of the latest disclosure. This is common when a fund's non-equity holdings are mostly cash or short-term money market instruments, which aren't assigned a credit rating the way bonds are.
When is the latest portfolio disclosure for UTI Healthcare Fund Direct-Growth?
The latest portfolio disclosure for UTI Healthcare Fund Direct-Growth is as of 31 Oct 2026. SEBI requires all mutual funds to disclose their complete portfolio holdings on a monthly basis, typically within 10 days of the end of each month.